Financial Snapshot

Revenue
$723.5M
TTM
Gross Margin
52.98%
TTM
Net Earnings
$157.7M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
343.34%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$727.7M
Q3 2024
Cash
Q3 2024
P/E
13.50
Nov 29, 2024 EST
Free Cash Flow
$170.2M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Revenue $644.4M $499.0M $437.8M $349.8M $322.4M $294.7M $240.2M $255.2M $251.5M $210.5M $229.7M $204.3M $118.4M $130.7M
YoY Change 29.14% 13.98% 25.13% 8.53% 9.4% 22.68% -5.88% 1.47% 19.48% -8.36% 12.43% 72.55% -9.41% -12.05%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Revenue $644.4M $499.0M $437.8M $349.8M $322.4M $294.7M $240.2M $255.2M $251.5M $210.5M $229.7M $204.3M $118.4M $130.7M
Cost Of Revenue $293.3M $250.1M $238.0M $206.5M $190.4M $187.7M $149.7M $151.0M $174.2M $159.2M $142.7M $114.0M $90.30M $80.60M
Gross Profit $351.1M $248.9M $199.7M $143.3M $131.9M $107.0M $90.50M $104.2M $77.30M $51.30M $87.00M $90.30M $28.10M $50.20M
Gross Profit Margin 54.49% 49.87% 45.63% 40.97% 40.92% 36.31% 37.68% 40.83% 30.74% 24.37% 37.88% 44.2% 23.73% 38.41%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Selling, General & Admin $80.39M $66.59M $68.92M $65.16M $63.11M $58.04M $50.90M $47.30M $47.00M $40.40M $36.30M $32.30M $31.60M $27.20M
YoY Change 20.72% -3.38% 5.78% 3.25% 8.73% 14.04% 7.61% 0.64% 16.34% 11.29% 12.38% 2.22% 16.18% -7.17%
% of Gross Profit 22.9% 26.76% 34.51% 45.46% 47.84% 54.25% 56.24% 45.39% 60.8% 78.75% 41.72% 35.77% 112.46% 54.18%
Research & Development $73.74M $74.77M $60.93M $67.23M $68.85M $57.56M $38.50M $41.50M $37.10M $28.40M $33.00M $30.50M $30.00M $29.20M
YoY Change -1.38% 22.71% -9.37% -2.36% 19.61% 49.52% -7.23% 11.86% 30.63% -13.94% 8.2% 1.67% 2.74% 17.27%
% of Gross Profit 21.0% 30.05% 30.51% 46.9% 52.19% 53.81% 42.54% 39.83% 47.99% 55.36% 37.93% 33.78% 106.76% 58.17%
Depreciation & Amortization $25.74M $12.60M $10.23M $9.030M $7.058M $6.053M $15.81M $14.57M $13.25M $14.45M $13.08M $11.50M $11.16M $10.77M
YoY Change 104.31% 23.2% 13.23% 27.94% 16.6% -61.71% 8.51% 9.96% -8.3% 10.47% 13.74% 3.05% 3.62%
% of Gross Profit 7.33% 5.06% 5.12% 6.3% 5.35% 5.66% 17.47% 13.98% 17.14% 28.17% 15.03% 12.74% 39.72% 21.45%
Operating Expenses $154.1M $141.4M $129.9M $132.4M $132.0M $115.6M $94.30M $88.80M $84.00M $68.80M $69.40M $62.80M $61.50M $56.40M
YoY Change 9.03% 8.86% -1.91% 0.32% 14.15% 22.6% 6.19% 5.71% 22.09% -0.86% 10.51% 2.11% 9.04% 4.06%
Operating Profit $197.0M $107.5M $69.89M $10.95M -$39.00K -$8.623M -$3.800M $15.40M -$6.700M -$17.50M $17.60M $27.50M -$33.40M -$6.200M
YoY Change 83.25% 53.82% 538.0% -28187.18% -99.55% 126.92% -124.68% -329.85% -61.71% -199.43% -36.0% -182.34% 438.71% -258.97%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Interest Expense $27.16M $1.846M $885.0K $374.0K $119.0K $243.0K -$400.0K -$800.0K -$700.0K -$400.0K -$800.0K -$500.0K -$200.0K -$300.0K
YoY Change 1371.18% 108.59% 136.63% 214.29% -51.03% -160.75% -50.0% 14.29% 75.0% -50.0% 60.0% 150.0% -33.33% -40.0%
% of Operating Profit 13.79% 1.72% 1.27% 3.41% -5.19% -4.55% -1.82%
Other Income/Expense, Net -$25.63M $8.543M $14.25M -$6.317M $60.27M -$1.303M $2.900M $0.00 -$2.800M $200.0K $500.0K $1.000M $1.800M $1.000M
YoY Change -399.99% -40.06% -325.61% -110.48% -4725.25% -144.93% -100.0% -1500.0% -60.0% -50.0% -44.44% 80.0% -1100.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Pretax Income $171.4M $116.0M $84.14M $4.637M $60.23M -$9.926M $1.200M $14.60M -$10.40M -$18.10M $17.20M $25.90M -$31.90M -$5.700M
YoY Change 47.67% 37.91% 1714.51% -92.3% -706.77% -927.17% -91.78% -240.38% -42.54% -205.23% -33.59% -181.19% 459.65% -385.0%
Income Tax $31.83M $23.48M $20.63M $3.540M $13.72M -$3.266M -$2.400M $4.800M -$7.600M -$7.400M $5.400M $7.800M -$39.60M $5.000M
% Of Pretax Income 18.58% 20.23% 24.52% 76.34% 22.79% -200.0% 32.88% 31.4% 30.12%
Net Earnings $137.5M $91.39M $62.12M $1.403M $48.94M -$5.738M $3.600M $9.800M -$2.800M -$10.70M $11.90M $18.10M $7.800M -$10.70M
YoY Change 50.51% 47.12% 4327.37% -97.13% -952.89% -259.39% -63.27% -450.0% -73.83% -189.92% -34.25% 132.05% -172.9% -29.14%
Net Earnings / Revenue 21.34% 18.31% 14.19% 0.4% 15.18% -1.95% 1.5% 3.84% -1.11% -5.08% 5.18% 8.86% 6.59% -8.19%
Basic Earnings Per Share $2.85 $1.88 $1.30 $0.03 $1.04 -$0.12
Diluted Earnings Per Share $2.60 $1.74 $1.25 $0.03 $0.98 -$0.12 $74.38K $206.3K -$62.22K -$254.8K $274.2K $417.1K $179.7K -$246.5K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Cash & Short-Term Investments $256.8M $175.8M $136.7M $105.6M $85.40M $89.20M $68.20M $72.90M $66.10M $67.80M $53.60M $50.20M $53.70M
YoY Change 46.11% 28.6% 29.43% 23.65% -4.26% 30.79% -6.45% 10.29% -2.51% 26.49% 6.77% -6.52%
Cash & Equivalents $144.3M $156.1M $126.4M $92.60M $73.70M $86.30M $65.60M $72.40M $66.10M $67.80M $53.60M $50.20M $53.70M
Short-Term Investments $112.5M $19.66M $10.32M $13.00M $11.70M $2.800M $2.600M $500.0K
Other Short-Term Assets $11.49M $9.998M $9.709M $10.90M $13.70M $9.700M $14.00M $4.700M $5.700M $24.70M $22.40M $25.80M $38.40M
YoY Change 14.94% 2.98% -10.93% -20.44% 41.24% -30.71% 197.87% -17.54% -76.92% 10.27% -13.18% -32.81%
Inventory $105.8M $103.6M $92.81M $96.80M $110.5M $69.30M $63.60M $79.80M $70.70M $82.30M $69.90M $51.40M $26.20M
Prepaid Expenses
Receivables $114.9M $88.80M $78.80M $66.00M $45.40M $52.20M $36.00M $26.80M $33.20M $22.90M $24.60M $48.30M $23.60M
Other Receivables $526.0K $171.0K $126.0K $400.0K $300.0K $0.00 $6.000M $0.00 $300.0K $200.0K $2.400M $1.900M $4.300M
Total Short-Term Assets $489.6M $378.3M $318.1M $279.7M $255.2M $220.3M $187.8M $184.1M $175.9M $198.0M $173.0M $177.6M $146.2M
YoY Change 29.41% 18.92% 13.74% 9.6% 15.84% 17.31% 2.01% 4.66% -11.16% 14.45% -2.59% 21.48%
Property, Plant & Equipment $315.6M $264.6M $271.5M $280.7M $253.5M $210.4M $180.5M $152.9M $142.2M $138.3M $116.6M $107.4M $95.60M
YoY Change 19.3% -2.55% -3.28% 10.73% 20.48% 16.57% 18.05% 7.52% 2.82% 18.61% 8.57% 12.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $15.21M $2.414M $3.985M
YoY Change 530.16% -39.42%
Other Assets $79.16M $59.38M $39.06M $30.20M $37.00M $40.50M $37.60M $40.40M $32.10M $10.50M $9.000M $2.100M $1.500M
YoY Change 33.31% 52.01% 29.35% -18.38% -8.64% 7.71% -6.93% 25.86% 205.71% 16.67% 328.57% 40.0%
Total Long-Term Assets $1.023B $363.7M $353.4M $351.5M $331.8M $293.3M $263.3M $243.6M $214.2M $191.4M $165.7M $151.8M $139.8M
YoY Change 181.39% 2.9% 0.54% 5.94% 13.13% 11.39% 8.09% 13.73% 11.91% 15.51% 9.16% 8.58%
Total Assets $1.513B $742.0M $671.5M $631.2M $587.0M $513.6M $451.1M $427.7M $390.1M $389.4M $338.7M $329.4M $286.0M
YoY Change
Accounts Payable $25.44M $20.50M $22.21M $24.40M $25.10M $31.30M $16.60M $16.20M $13.90M $10.20M $20.40M $17.70M $10.60M
YoY Change 24.08% -7.71% -8.96% -2.79% -19.81% 88.55% 2.47% 16.55% 36.27% -50.0% 15.25% 66.98%
Accrued Expenses $197.9M $66.74M $70.31M $74.50M $55.20M $56.10M $40.90M $31.40M $31.40M $26.50M $19.40M $28.60M $35.80M
YoY Change 196.54% -5.08% -5.62% 34.96% -1.6% 37.16% 30.25% 0.0% 18.49% 36.6% -32.17% -20.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $436.0K $3.046M $2.202M $12.30M $7.700M $18.20M $6.300M $5.400M $10.90M $7.600M $22.10M $22.10M $1.100M
YoY Change -85.69% 38.33% -82.1% 59.74% -57.69% 188.89% 16.67% -50.46% 43.42% -65.61% 0.0% 1909.09%
Total Short-Term Liabilities $225.4M $94.86M $103.8M $112.2M $90.00M $106.8M $67.20M $60.60M $60.00M $62.60M $65.40M $72.00M $53.50M
YoY Change 137.62% -8.62% -7.48% 24.67% -15.73% 58.93% 10.89% 1.0% -4.15% -4.28% -9.17% 34.58%
Long-Term Debt $589.6M $72.84M $74.78M $34.20M $39.40M $32.00M $40.80M $32.40M $30.20M $36.10M $10.10M $16.00M $13.00M
YoY Change 709.43% -2.59% 118.64% -13.2% 23.13% -21.57% 25.93% 7.28% -16.34% 257.43% -36.88% 23.08%
Other Long-Term Liabilities $58.51M $45.48M $46.89M $35.40M $29.20M $9.400M $7.900M $4.100M $4.500M $3.000M $4.600M $5.000M $7.700M
YoY Change 28.63% -2.99% 32.45% 21.23% 210.64% 18.99% 92.68% -8.89% 50.0% -34.78% -8.0% -35.06%
Total Long-Term Liabilities $648.1M $118.3M $121.7M $69.60M $68.60M $41.40M $48.70M $36.50M $34.70M $39.10M $14.70M $21.00M $20.70M
YoY Change 447.72% -2.75% 74.8% 1.46% 65.7% -14.99% 33.42% 5.19% -11.25% 165.99% -30.0% 1.45%
Total Liabilities $873.5M $213.3M $226.0M $228.9M $205.6M $181.1M $117.3M $98.50M $94.60M $107.5M $87.20M $95.90M $77.50M
YoY Change 309.46% -5.61% -1.26% 11.33% 13.53% 54.39% 19.09% 4.12% -12.0% 23.28% -9.07% 23.74%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Basic Shares Outstanding 48.27M 48.55M 47.78M 47.04M 46.98M 46.40M
Diluted Shares Outstanding 53.00M 52.43M 49.78M 49.12M 49.91M 46.40M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.13 Billion

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Industry: Pharmaceutical Preparations Peers: Amylyx Pharmaceuticals, Inc. CinCor Pharma, Inc. JOHNSON & JOHNSON NGM BIOPHARMACEUTICALS INC PLIANT THERAPEUTICS, INC. SUPERNUS PHARMACEUTICALS, INC. Tilray Brands, Inc.